Cerebral Amyloid Angiopathy Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Cerebral Amyloid Angiopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals200 enrolled57 locationsNCT06393712
Recruiting
Not Applicable

Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)

Cerebral Amyloid AngiopathyStrokeMoyamoya Disease
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta20 enrolled1 locationNCT06714097
Recruiting

SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)

Cerebral Amyloid Angiopathy
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta500 enrolled1 locationNCT04204642
Recruiting
Phase 2

A Study of AMDX-2011P in Participants With CAA

Cerebral Amyloid Angiopathy
Amydis Inc.25 enrolled1 locationNCT05709314
Recruiting
Phase 2

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar
Huashan Hospital80 enrolled3 locationsNCT07026994
Recruiting

Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

Cerebral Amyloid AngiopathyCAA - Cerebral Amyloid Angiopathy
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta86 enrolled1 locationNCT06933212
Recruiting
Phase 2

Treatment Of Stroke reCurrence in Cerebral Amyloid Angiopathy with TraneXamic Acid (TOSCCAA- TXA)

Cerebral Amyloid Angiopathy
Alfred Health60 enrolled2 locationsACTRN12624001477516
Recruiting

Prognosis of Cerebral Small Vessel Disease

Cerebral Amyloid AngiopathyCadasilSmall Vessel Cerebrovascular Disease+1 more
Insel Gruppe AG, University Hospital Bern900 enrolled1 locationNCT05734378